Investments
57Portfolio Exits
4
Want to inform investors similar to C&D Emerging Investment about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
C&D Emerging Investment Investments
57 Investments
C&D Emerging Investment has made 57 investments. Their latest investment was in OriCell Therapeutics as part of their Series B - II on February 2, 2023.
C&D Emerging Investment Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
2/28/2023 | Series B - II | OriCell Therapeutics | $45M | No | 2 | |
2/28/2023 | Series B - II | Origiencell | $45M | No | 3 | |
1/18/2023 | Series C | GenScript ProBio | $220M | Yes | 7 | |
1/3/2023 | Series A | |||||
12/31/2022 | Private Equity - II |
Date | 2/28/2023 | 2/28/2023 | 1/18/2023 | 1/3/2023 | 12/31/2022 |
|---|---|---|---|---|---|
Round | Series B - II | Series B - II | Series C | Series A | Private Equity - II |
Company | OriCell Therapeutics | Origiencell | GenScript ProBio | ||
Amount | $45M | $45M | $220M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 3 | 7 |
C&D Emerging Investment Portfolio Exits
4 Portfolio Exits
C&D Emerging Investment has 4 portfolio exits. Their latest portfolio exit was China Micro Semiconductor on August 05, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/5/2022 | IPO | Public | 1 | ||
Date | 8/5/2022 | |||
|---|---|---|---|---|
Exit | IPO | |||
Companies | ||||
Valuation | ||||
Acquirer | Public | |||
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.